Zobrazeno 1 - 10
of 5 303
pro vyhledávání: '"Neelapu SS"'
Publikováno v:
Blood [Blood] 2018 Feb 01; Vol. 131 (5), pp. 587-588.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::193873be36c0453832f3e8867e034de4
https://europepmc.org/articles/PMC5794504/
https://europepmc.org/articles/PMC5794504/
Autor:
Lunning MA; University of Nebraska, Omaha, Nebraska, USA., Wang HL; Kite, A Gilead Company, Santa Monica, California, USA., Hu ZH; Kite, A Gilead Company, Santa Monica, California, USA., Locke FL; Moffitt Cancer Center, Tampa, Florida, USA., Siddiqi T; City of Hope National Medical Center, Duarte, California, USA., Jacobson CA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ahmed S; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Miklos DB; Stanford University School of Medicine, Stanford, California, USA., Lin Y; Mayo Clinic, Rochester, Minnesota, USA., Hill BT; Cleveland Clinic Foundation, Cleveland, Ohio, USA., Ghobadi A; Washington University School of Medicine, St Louis, Missouri, USA., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Westin J; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Dieyi C; Kite, A Gilead Company, Santa Monica, California, USA., Field P; Oxford PharmaGenesis, Oxford, UK., Miao H; Kite, A Gilead Company, Santa Monica, California, USA., Shahani SA; Kite, A Gilead Company, Santa Monica, California, USA., Patel A; Kite, A Gilead Company, Santa Monica, California, USA., Spooner C; Kite, A Gilead Company, Santa Monica, California, USA., Fu C; Kite, A Gilead Company, Santa Monica, California, USA., Muramoto D; Kite, A Gilead Company, Santa Monica, California, USA., Xu H; Kite, A Gilead Company, Santa Monica, California, USA., Pasquini MC; CIBMTR, Milwaukee, Wisconsin, USA.
Publikováno v:
American journal of hematology [Am J Hematol] 2024 May; Vol. 99 (5), pp. 880-889. Date of Electronic Publication: 2024 Mar 19.
Autor:
Locke FL; Moffitt Cancer Center, Tampa, Florida. Electronic address: frederick.locke@moffitt.org., Neelapu SS; M.D. Anderson Cancer Center, Houston, Texas., Bartlett NL; Washington University School of Medicine, St. Louis, Missouri., Lekakis LJ; University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, Florida., Jacobson CA; Dana-Farber Cancer Institute, Boston, Massachusetts., Braunschweig I; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Oluwole OO; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Siddiqi T; City of Hope National Medical Center, Duarte, California., Lin Y; Mayo Clinic, Rochester, Minnesota., Timmerman JM; UCLA David Geffen School of Medicine, Los Angeles, California., Kersten MJ; Amsterdam UMC, University of Amsterdam, Amsterdam, Cancer Center Amsterdam, Netherlands, on behalf of HOVON/LLPC., Zheng Y; Kite, a Gilead Company, Santa Monica, California., Zhang T; Kite, a Gilead Company, Santa Monica, California., Nater J; Kite, a Gilead Company, Santa Monica, California., Shen R; Kite, a Gilead Company, Santa Monica, California., Miao H; Kite, a Gilead Company, Santa Monica, California., Kim JJ; Kite, a Gilead Company, Santa Monica, California., Miklos DB; Stanford University School of Medicine, Stanford, California.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Nov; Vol. 30 (11), pp. 1065-1079. Date of Electronic Publication: 2024 Aug 24.
Autor:
Prasad R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman A; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman L; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Darbaniyan F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Blumenberg V; University Hospital, LMU Munich, Germany., Schubert ML; University Clinic Heidelberg, Germany., Mor U; Weizmann Institute of Science, Rehovot, Israel., Zamir E; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmidt S; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hayase T; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Chia-Chi C; The University of Texas MD Anderson Cancer Center, United States., McDaniel LK; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Flores I; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Strati P; The University of Texas MD Anderson Cancer Center, United States., Nair R; The University of Texas MD Anderson Cancer Center, United States., Chihara D; The University of Texas MD Anderson Cancer Center, United States., Fayad LE; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States., Ahmed S; The University of Texas MD Anderson Cancer Center, United States., Iyer SP; The University of Texas MD Anderson Cancer Center, United States., Wang ML; The University of Texas MD Anderson Cancer Center, United States., Jain P; The University of Texas MD Anderson Cancer Center, United States., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Westin JR; The University of Texas MD Anderson Cancer Center, United States., Arora R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Turner JG; Moffitt Cancer Center, Tampa, Florida, United States., Khawaja F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Wu R; The University of Texas MD Anderson Cancer Center, United States., Dennison JB; The University of Texas MD Anderson Cancer Center, United States., Menges M; Moffitt Cancer Center, Tampa, Florida, United States., Hidalgo-Vargas M; Moffitt Cancer Center, Tampa, Florida, United States., Reid KM; Moffitt Cancer Center, Tampa, Florida, United States., Davila ML; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Dreger P; University Clinic Heidelberg, Heidelberg, Germany., Korell F; University Hospital Heidelberg, Heidelberg, Germany., Schmitt A; University Clinic Heidelberg, Germany., Tanner MR; The University of Texas MD Anderson Cancer Center, United States., Champlin RE; The University of Texas MD Anderson Cancer Center, United States., Flowers CR; The University of Texas MD Anderson Cancer Center, United States., Shpall EJ; The University of Texas MD Anderson Cancer Center, United States., Hanash S; The University of Texas MD Anderson Cancer Center, United States., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Schmitt M; University Clinic Heidelberg, Germany., Subklewe M; University Hospital, LMU Munich, Munich, Germany., Fahrmann J; The University of Texas MD Anderson Cancer Center, United States., Stein-Thoeringer C; University of Tuebingen, Tuebingen, Germany., Elinav E; Weizmann Institute of Science, Rehovot, Israel., Jain MD; Moffitt Cancer Center, Tampa, Florida, United States., Hayase E; The University of Texas MD Anderson Cancer Center, United States., Jenq RR; The University of Texas MD Anderson Cancer Center, United States., Saini NY; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Publikováno v:
Blood [Blood] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.
Autor:
Jain MD; Moffitt Cancer Center, Tampa, FL., Spiegel JY; University of Miami Miller School of Medicine, Miami, FL., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX., Tamaresis J; Stanford University Medical Center, Stanford, CA., Ghobadi A; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO., Lin Y; Mayo Clinic, Rochester, MN., Lekakis L; University of Miami Miller School of Medicine, Miami, FL., Reagan P; University of Rochester Medical Center, Rochester, NY., Oluwole O; Vanderbilt-Ingram Cancer Center, Nashville, TN., McGuirk J; University of Kansas Medical Center, Kansas City, KS., Deol A; Karmanos Center Institute/Wayne State University, Detroit, MI., Dorritie KA; UPMC Hillman Cancer Center, Pittsburgh, PA., Sehgal AR; UPMC Hillman Cancer Center, Pittsburgh, PA., Goy A; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ., Hill BT; Cleveland Clinic, Cleveland, OH., Andreadis C; University of CA San Francisco, San Francisco, CA., Munoz J; Mayo Clinic Arizona, Phoenix, AZ., Ulrickson M; Banner MD Anderson Cancer Center, Gilbert, AZ., Westin J; The University of Texas MD Anderson Cancer Center, Houston, TX., Chavez JC; Moffitt Cancer Center, Tampa, FL., Patel D; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO., Jacobs MT; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO., Bansal R; Mayo Clinic, Rochester, MN., Bennani NN; Mayo Clinic, Rochester, MN., Patel VG; Vanderbilt-Ingram Cancer Center, Nashville, TN., Rapoport AP; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD., Vose JM; University of Nebraska Medical Center, Omaha, NE., Miklos DB; Stanford University Medical Center, Stanford, CA., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, TX., Locke FL; Moffitt Cancer Center, Tampa, FL., Lunning M; University of Nebraska Medical Center, Omaha, NE., Dahiya S; Stanford University Medical Center, Stanford, CA.; University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 20; Vol. 42 (30), pp. 3581-3592. Date of Electronic Publication: 2024 Aug 02.
Autor:
Wu SY; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Fang PQ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Fetooh A; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Manzar GS; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Corrigan KL; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Schrank BR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Nasr L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas., Chihara D; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Castillo LEM; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Steiner RE; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Jain P; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Strati P; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Nastoupil LJ; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja BS; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Pinnix CC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Advances in radiation oncology [Adv Radiat Oncol] 2024 Sep 27; Vol. 9 (12), pp. 101648. Date of Electronic Publication: 2024 Sep 27 (Print Publication: 2024).
Autor:
Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dudzinski SO; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cha EE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Corrigan KL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nasr LF; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sallard G; Baylor College of Medicine, Houston, Texas., Ahmed S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chihara D; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daher M; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: pfang@mdanderson.org.
Publikováno v:
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Sep 19. Date of Electronic Publication: 2024 Sep 19.
Autor:
Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cha EE; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Corrigan KL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Yoder AK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Schrank BR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nasr LF; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Chihara D; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Castillo LM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nair R; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Jain P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rodriguez MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Strati P; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gunther JR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dabaja BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Pinnix CC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wu SY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fang PQ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Publikováno v:
Frontiers in oncology [Front Oncol] 2024 Sep 11; Vol. 14, pp. 1447020. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
Autor:
Gurumurthi A; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chin CK; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Haematology, Royal Perth Hospital, Perth, WA, Australia.; University of Western Australia, Perth, WA, Australia., Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fowler NH; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; BostonGene, Waltham, MA, USA., Strati P; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hagemeister FB; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad LE; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin JR; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Obi C; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arafat J; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Steiner RE; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Neelapu SS; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nastoupil LJ; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
EClinicalMedicine [EClinicalMedicine] 2024 Jul 27; Vol. 74, pp. 102747. Date of Electronic Publication: 2024 Jul 27 (Print Publication: 2024).